VCAM1 and Miyoshi myopathy: As shown in Figure 3C,D, daratumumab, isatuximab (1 μg/mL) or the combination of both significantly impeded the adhesion to VCAM-1 of MM cells, with no significant differences with anti-CD49d positive control.